Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $HIMS are available with SpikePanel Pro.
Hims Option Activity and Subscriber Model Estimates After CFO Sale
Unusual options and subscriber/ARPU model estimates highlight Q3 focus
D1 +0.5% · +5d -1.4%
›2 waves of this story
2026-09-25 Insider sale may draw attention to internal confidence
2026-09-30 Unusual options and subscriber/ARPU model estimates highlight Q3 focus
RegulationBull
Hims advances peptide push: BPC-157 human trial starts
Arkansas RCT marks first US clinical trial for BPC-157, bolstering peptide strategy
D1 -1.8% · +5d +3.7%
›6 waves of this story
2026-08-12 Lilly's suits against black-market sellers could shape regulatory landscape for Hims' legal peptide offering
2026-08-26 New NAD ruling mandates ad wording changes, impacting product marketing
2026-09-09 Q2 announced plans to offer peptides by end-2026; hiring signals execution
2026-09-15 New hire from a leading peptide manufacturer strengthens in-house peptide production
2026-09-17 Following the hiring of a peptide production expert, a new Quality Director role for peptide API signals deepening in-house manufacturing plans
2026-09-27 Arkansas RCT marks first US clinical trial for BPC-157, bolstering peptide strategy
ProductBull
HIMS Launches AI-Powered App Experience for Weight Loss Members
New feature uses treatment history and outcomes to create a feedback loop; CEO Elshenawy highlights personalization edge
D1 +3.1% · +5d +0.1%
Analyst
J.P. Morgan re-initiates coverage on HIMS with Hold and $32 PT
Analyst sees Novo partnership offsetting GLP-1 headwinds, positive on vertical integration and brand scale
D1 +0.3% · +5d +1.7%
AnalystBull
Analysts expect HIMS Q3 net income positive, revenue forecast above $900M
Multiple sources forecast Q3 revenue up >50% YoY; profitability could trigger re-rating
D1 +0.3% · +5d +1.7%
CapitalBear
HIMS Faces Securities Lawsuit, DJS Law Group Seeks Investors
Company announcement reveals lawsuit, potential disclosure issues, adding legal risk
D1 -3.0% · +5d -1.1%
Regulation
FDA Warning Escalates, HIMS Pressured but Q2 Results Strong
Q2 revenue up 38.2% to $753M, raises guidance, but FDA regulatory risk persists
D1 +0.8% · +5d -4.3%
›3 waves of this story
2026-09-02 FDA tightens rules on compounded GLP-1s, impacting HIMS offerings
2026-09-03 FDA names 30 firms, HIMS stock falls, but company raises full-year guidance, mixed signals
2026-09-03 Q2 revenue up 38.2% to $753M, raises guidance, but FDA regulatory risk persists
CompanyBull
Hims officially enters Australia, marking first Asia-Pacific expansion
Company announcement confirms entry via Eucalyptus acquisition, paving way for international growth
D1 -3.9% · +5d -1.9%
RegulationBear
Hims & Hers shares drop 8% on Visa monitoring dispute
Hims Option Activity and Subscriber Model Estimates After CFO Sale
Unusual options and subscriber/ARPU model estimates highlight Q3 focus
D1 +0.5% · +5d -1.4%
›2 waves of this story
2026-09-25 Insider sale may draw attention to internal confidence
2026-09-30 Unusual options and subscriber/ARPU model estimates highlight Q3 focus
RegulationBull
Hims advances peptide push: BPC-157 human trial starts
Arkansas RCT marks first US clinical trial for BPC-157, bolstering peptide strategy
D1 -1.8% · +5d +3.7%
›6 waves of this story
2026-08-12 Lilly's suits against black-market sellers could shape regulatory landscape for Hims' legal peptide offering
2026-08-26 New NAD ruling mandates ad wording changes, impacting product marketing
2026-09-09 Q2 announced plans to offer peptides by end-2026; hiring signals execution
2026-09-15 New hire from a leading peptide manufacturer strengthens in-house peptide production
2026-09-17 Following the hiring of a peptide production expert, a new Quality Director role for peptide API signals deepening in-house manufacturing plans
2026-09-27 Arkansas RCT marks first US clinical trial for BPC-157, bolstering peptide strategy
ProductBull
HIMS Launches AI-Powered App Experience for Weight Loss Members
New feature uses treatment history and outcomes to create a feedback loop; CEO Elshenawy highlights personalization edge
D1 +3.1% · +5d +0.1%
Analyst
J.P. Morgan re-initiates coverage on HIMS with Hold and $32 PT
Analyst sees Novo partnership offsetting GLP-1 headwinds, positive on vertical integration and brand scale
D1 +0.3% · +5d +1.7%
AnalystBull
Analysts expect HIMS Q3 net income positive, revenue forecast above $900M
Multiple sources forecast Q3 revenue up >50% YoY; profitability could trigger re-rating
D1 +0.3% · +5d +1.7%
CapitalBear
HIMS Faces Securities Lawsuit, DJS Law Group Seeks Investors
Company announcement reveals lawsuit, potential disclosure issues, adding legal risk
D1 -3.0% · +5d -1.1%
Regulation
FDA Warning Escalates, HIMS Pressured but Q2 Results Strong
Q2 revenue up 38.2% to $753M, raises guidance, but FDA regulatory risk persists
D1 +0.8% · +5d -4.3%
›3 waves of this story
2026-09-02 FDA tightens rules on compounded GLP-1s, impacting HIMS offerings
2026-09-03 FDA names 30 firms, HIMS stock falls, but company raises full-year guidance, mixed signals
2026-09-03 Q2 revenue up 38.2% to $753M, raises guidance, but FDA regulatory risk persists
CompanyBull
Hims officially enters Australia, marking first Asia-Pacific expansion
Company announcement confirms entry via Eucalyptus acquisition, paving way for international growth
D1 -3.9% · +5d -1.9%
RegulationBear
Hims & Hers shares drop 8% on Visa monitoring dispute
